Key Points:
- The New England Journal of Medicine has published the results of the pivotal BLUE-C study on Cologuard Plus™.
- The study evaluates the effectiveness of Cologuard Plus™, a noninvasive stool DNA test, in detecting colorectal cancer and precancerous lesions.
- Cologuard Plus™ demonstrated high sensitivity in detecting colorectal cancer and advanced adenomas.
- The test’s performance was compared to a fecal immunochemical test (FIT) and showed superior sensitivity in detecting colorectal cancer and advanced adenomas.
- The BLUE-C study included a diverse population across the United States, contributing to the test’s real-world applicability.